Announcements and Notices - [Overseas Regulatory Announcement - Other]

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Overseas Regulatory Announcement - Form 8-K

Announcements and Notices - [Share Scheme]

Grant Of Share Options And Restricted Share Units

Announcements and Notices - [Change of Company Name]

Proposed Change Of English Name Of Company

Announcements and Notices - [Overseas Regulatory Announcement - Trading Update]

Overseas Regulatory Announcement - Form 10-Q

Announcements and Notices - [Inside Information / Other - Business Update / Quarterly Results]

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeiGene (6160 HK)

Overseas Regulatory Announcement - Form 8-K

Grant Of Share Options And Restricted Share Units

Proposed Change Of English Name Of Company

Overseas Regulatory Announcement - Form 10-Q

Inside Information - Unaudited Results For The Three And Nine Months Ended September 30, 2024 Of Beigene, Ltd. And Business Updates

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)